{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T20:28:42Z","timestamp":1769286522323,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":2300,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1194\/jlr.p042176","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T04:49:43Z","timestamp":1387255783000},"page":"1139-1149","source":"Crossref","is-referenced-by-count":47,"title":["Bioactive lipid mediators in polycystic kidney disease"],"prefix":"10.1016","volume":"55","author":[{"given":"Jelena","family":"Klawitter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jost","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"McFann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaleab Z.","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godela","family":"Brosnahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Cadnapaphornchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berenice","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Schrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.P042176_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/ajkd.2001.27720","article-title":"Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality","volume":"38","author":"Perrone","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.P042176_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1871528110908050369","article-title":"Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes","volume":"8","author":"Filiopoulos","year":"2009","journal-title":"Inflamm. Allergy Drug Targets."},{"key":"10.1194\/jlr.P042176_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1440-1797.2012.01572.x","article-title":"Oxidative stress, anti-oxidant therapies and chronic kidney disease","volume":"17","author":"Small","year":"2012","journal-title":"Nephrology (Carlton)."},{"key":"10.1194\/jlr.P042176_bib4","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2215\/CJN.04610511","article-title":"Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease","volume":"6","author":"Perrone","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.P042176_bib5","first-page":"211","article-title":"Cardiac involvement in autosomal-dominant polycystic kidney disease: a hypertensive heart disease","volume":"56","author":"Bardaj\u00ed","year":"2001","journal-title":"Clin. Nephrol."},{"key":"10.1194\/jlr.P042176_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1573402111309010005","article-title":"Left ventricular hypertrophy in ADPKD: changing demographics","volume":"9","author":"Alam","year":"2013","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1194\/jlr.P042176_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/CIRCULATIONAHA.109.914507","article-title":"Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study","volume":"122","author":"Mitchell","year":"2010","journal-title":"Circulation."},{"key":"10.1194\/jlr.P042176_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2010.05.033","article-title":"Arterial stiffness and declines in individuals with normal renal function\/early chronic kidney disease","volume":"212","author":"Tomiyama","year":"2010","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.P042176_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00398.x","article-title":"Biomarkers of inflammation and progression of chronic kidney disease","volume":"68","author":"Tonelli","year":"2005","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.P042176_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000101369","article-title":"Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function","volume":"27","author":"Borresen","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1194\/jlr.P042176_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.108.816108","article-title":"Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study","volume":"119","author":"Lieb","year":"2009","journal-title":"Circulation."},{"key":"10.1194\/jlr.P042176_bib12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/HYPERTENSIONAHA.107.105668","article-title":"Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection","volume":"51","author":"Schnabel","year":"2008","journal-title":"Hypertension."},{"key":"10.1194\/jlr.P042176_bib13","first-page":"619","article-title":"Cytokine profile in autosomal dominant polycystic kidney disease","volume":"41","author":"Merta","year":"1997","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1194\/jlr.P042176_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000315859","article-title":"Effects of specific genes activating RAGE on polycystic kidney disease","volume":"32","author":"Park","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"10.1194\/jlr.P042176_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1475-097X.2010.00943.x","article-title":"Elevated augmentation index derived from peripheral arterial tonometry is associated with abnormal ventricular-vascular coupling","volume":"30","author":"Heffernan","year":"2010","journal-title":"Clin. Physiol. Funct. Imaging."},{"key":"10.1194\/jlr.P042176_bib16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/ndt\/gfq806","article-title":"Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease","volume":"26","author":"Heffernan","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.P042176_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2215\/CJN.04140510","article-title":"Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease","volume":"6","author":"Menon","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.P042176_bib18","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease","volume":"16","author":"van Dijk","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.P042176_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/08860220601038892","article-title":"Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease","volume":"29","author":"Namli","year":"2007","journal-title":"Ren. Fail."},{"key":"10.1194\/jlr.P042176_bib20","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00214.2004","article-title":"Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors","volume":"287","author":"Harris","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1194\/jlr.P042176_bib21","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI1500","article-title":"Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells","volume":"101","author":"Hern\u00e1ndez-Perera","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.P042176_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0008-6363(03)00515-7","article-title":"Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells","volume":"59","author":"Mulhaupt","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1194\/jlr.P042176_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/01.ATV.0000059384.34874.F0","article-title":"Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients","volume":"23","author":"Rezaie-Majd","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P042176_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2174\/0929867306666220320220844","article-title":"12-Lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors","volume":"6","author":"Dailey","year":"1999","journal-title":"Curr. Med. Chem."},{"key":"10.1194\/jlr.P042176_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-5381.1994.tb13081.x","article-title":"Relative roles of nitric oxide and cyclo-oxygenase and lipoxygenase products of arachidonic acid in the contractile responses of rat renal arcuate arteries","volume":"112","author":"Wu","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1194\/jlr.P042176_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tcm.2004.04.003","article-title":"Lipoxygenase pathways in atherogenesis","volume":"14","author":"Zhao","year":"2004","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1194\/jlr.P042176_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1681\/ASN.2004070568","article-title":"Novel interactions between TGF-{beta}1 actions and the 12\/15-lipoxygenase pathway in mesangial cells","volume":"16","author":"Kim","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.P042176_bib28","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science."},{"key":"10.1194\/jlr.P042176_bib29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1194\/jlr.P042176_bib30","doi-asserted-by":"crossref","first-page":"F496","DOI":"10.1152\/ajprenal.00350.2004","article-title":"Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases","volume":"289","author":"Imig","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1194\/jlr.P042176_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/CS20050251","article-title":"Eicosanoids and renal vascular function in diseases","volume":"111","author":"Imig","year":"2006","journal-title":"Clin. Sci. (Lond.)."},{"key":"10.1194\/jlr.P042176_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00041552-200403000-00009","article-title":"Role of 20-hydroxyei\u00adcosatetraenoic acid and epoxyeicosatrienoic acids in hypertension","volume":"13","author":"Sarkis","year":"2004","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1194\/jlr.P042176_bib33","first-page":"6307","article-title":"Lipoxygenase modulation to reverse carcinogenesis","volume":"61","author":"Shureiqi","year":"2001","journal-title":"Cancer Res."},{"key":"10.1194\/jlr.P042176_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1194\/jlr.P042176_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/rcm.3331","article-title":"Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography\/electrospray ionisation tandem mass spectrometry","volume":"22","author":"Masoodi","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1194\/jlr.P042176_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.P042176_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.P042176_bib38","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science."},{"key":"10.1194\/jlr.P042176_bib39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1042\/BST0391240","article-title":"Lipidomics of polyunsaturated-fatty-acid-derived oxygenated metabolites","volume":"39","author":"Massey","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1194\/jlr.P042176_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.prostaglandins.2006.05.025","article-title":"Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids","volume":"82","author":"Medhora","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1194\/jlr.P042176_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0005-2760(91)90230-F","article-title":"Stereospecificity of the hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids produced by cultured bovine endothelial cells","volume":"1085","author":"Baer","year":"1991","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.P042176_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0163-7827(96)00008-2","article-title":"Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid","volume":"35","author":"K\u03bchn","year":"1996","journal-title":"Prog. Lipid Res."},{"key":"10.1194\/jlr.P042176_bib43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-2275(20)32149-0","article-title":"13-(S)-hydroxyoctadecadienoic acid (13-HODE) incorporation and conversion to novel products by endothelial cells","volume":"40","author":"Fang","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P042176_bib44","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1586\/14779072.3.6.1099","article-title":"Biologic relevance of lipoxygenase isoforms in atherogenesis","volume":"3","author":"Kuhn","year":"2005","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1194\/jlr.P042176_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.plipres.2010.10.005","article-title":"Functional and pathological roles of the 12- and 15-lipoxygenases","volume":"50","author":"Dobrian","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1194\/jlr.P042176_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/MNH.0b013e32831a9df7","article-title":"Emerging roles for eicosanoids in renal diseases","volume":"18","author":"Camara","year":"2009","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1194\/jlr.P042176_bib47","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.ki.5002192","article-title":"Physiologic and pathophysiologic roles of lipid mediators in the kidney","volume":"71","author":"Hao","year":"2007","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.P042176_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1194\/jlr.P042176_bib49","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/ndt\/16.12.2283","article-title":"Cytochrome P450 metabolites of arachidonic acid: novel regulators of renal function","volume":"16","author":"Hoagland","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.P042176_bib50","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing","volume":"192","author":"Serhan","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1194\/jlr.P042176_bib51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.atherosclerosis.2012.03.022","article-title":"Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease","volume":"222","author":"Theken","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.P042176_bib52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/hh2101.099268","article-title":"Cytochrome p450 and vascular homeostasis","volume":"89","author":"Fleming","year":"2001","journal-title":"Circ. Res."},{"issue":"Spec No 2","key":"10.1194\/jlr.P042176_bib53","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1093\/hmg\/ddl183","article-title":"Genetic susceptibility to myocardial infarction and coronary artery disease","volume":"15","author":"Topol","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1194\/jlr.P042176_bib54","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.2174\/138161208786264115","article-title":"Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics","volume":"14","author":"List\u00ec","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1194\/jlr.P042176_bib55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0952-3278(91)90087-L","article-title":"Gas chromatographic-mass spectrometric analysis of lipoxygenase products in post-ischemic rabbit myocardium","volume":"42","author":"Hughes","year":"1991","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids."},{"key":"10.1194\/jlr.P042176_bib56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ki.1994.374","article-title":"Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members","volume":"46","author":"Barrett","year":"1994","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.P042176_bib57","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.P042176_bib58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.ajkd.2007.09.020","article-title":"Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease","volume":"51","author":"Wang","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.P042176_bib59","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.2007080939","article-title":"Products of 12\/15-lipoxygenase upregulate the angiotensin II receptor","volume":"19","author":"Xu","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.P042176_bib60","doi-asserted-by":"crossref","first-page":"F985","DOI":"10.1152\/ajprenal.00181.2002","article-title":"Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells","volume":"283","author":"Reddy","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1194\/jlr.P042176_bib61","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(01)01538-7","article-title":"Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease","volume":"87","author":"Brunner","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1194\/jlr.P042176_bib62","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.95.3.588","article-title":"Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension","volume":"95","author":"Laursen","year":"1997","journal-title":"Circulation."},{"key":"10.1194\/jlr.P042176_bib63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/01.HYP.0000153321.13792.b9","article-title":"Angiotensin II and the endothelium: diverse signals and effects","volume":"45","author":"Watanabe","year":"2005","journal-title":"Hypertension."},{"key":"10.1194\/jlr.P042176_bib64","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/ATVBAHA.109.185793","article-title":"Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis","volume":"29","author":"Kim","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P042176_bib65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1161\/CIRCRESAHA.107.155556","article-title":"15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression","volume":"102","author":"Viita","year":"2008","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.P042176_bib66","first-page":"2256","article-title":"Elevated expression of 12\/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma","volume":"63","author":"Shappell","year":"2003","journal-title":"Cancer Res."},{"key":"10.1194\/jlr.P042176_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1523-1755.2001.00768.x","article-title":"Angiogenesis in autosomal-dominant polycystic kidney disease","volume":"60","author":"Bello-Reuss","year":"2001","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.P042176_bib68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ki.2010.355","article-title":"Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease","volume":"79","author":"Reed","year":"2011","journal-title":"Kidney Int."},{"issue":"Suppl 1","key":"10.1194\/jlr.P042176_bib69","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1079\/BJN2001457","article-title":"Regulatory potential of n-3 fatty acids in immunological and inflammatory processes","volume":"87","author":"Grimm","year":"2002","journal-title":"Br. J. Nutr."},{"key":"10.1194\/jlr.P042176_bib70","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1194\/jlr.P042176_bib71","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ajh.21170","article-title":"Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake","volume":"83","author":"Poulsen","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1194\/jlr.P042176_bib72","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1152\/ajpregu.00664.2001","article-title":"Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II","volume":"283","author":"Alonso-Galicia","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1194\/jlr.P042176_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1124\/jpet.109.159863","article-title":"20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling","volume":"332","author":"Cheng","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1194\/jlr.P042176_bib74","doi-asserted-by":"crossref","first-page":"F575","DOI":"10.1152\/ajprenal.90705.2008","article-title":"Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD","volume":"296","author":"Park","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1194\/jlr.P042176_bib75","doi-asserted-by":"crossref","first-page":"F144","DOI":"10.1152\/ajprenal.0064.2001","article-title":"Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule","volume":"282","author":"Escalante","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1194\/jlr.P042176_bib76","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1440-1681.2002.03762.x","article-title":"Nitric oxide inhibits renal cytochrome P450-dependent epoxygenases in the rat","volume":"29","author":"Oyekan","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"Suppl 1","key":"10.1194\/jlr.P042176_bib77","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1038\/sj.bjp.0707489","article-title":"Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus","volume":"153","author":"Serhan","year":"2008","journal-title":"Br. J. Pharmacol."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520352779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520352779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.P042176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T02:26:31Z","timestamp":1688869591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520352779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0022227520352779"],"URL":"https:\/\/doi.org\/10.1194\/jlr.p042176","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}